Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas

Genes Chromosomes and Cancer

Volumn 47, Issue 2, 2008, Pages 175-184

  Helsing, Per ^a   Nymoen, Dag Andre ^a   Ariansen, Sarah ^a   Steine, Solrun J ^b   Maehle, Lovise ^a   Aamdal, Steinar ^a   Langmark, Frøydis ^c   Loeb, Mitchell ^d   Akslen, Lars A ^b,e   Molven, Anders ^b,e   Andresen, Per Arne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d SINTEF   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLYCINE; LEUCINE; PROLINE; VALINE;

ADULT; ARTICLE; CDK4 GENE; CDKN2A GENE; EXON; FAMILY HISTORY; FEMALE; GENE DELETION; GENE MUTATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; NORWAY; NUCLEOTIDE SEQUENCE; ONCOGENE; POPULATION GENETICS; PREVALENCE; PRIORITY JOURNAL; PROBABILITY;

ADULT; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CROSS-SECTIONAL STUDIES; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENES, P16; HUMANS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PREVALENCE; SKIN NEOPLASMS; VARIATION (GENETICS);

EID: 38049021654     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20518     Document Type: Article

References (44)

1. Auroy S, Avril ME, Chompret A, Pham D, Goldstein AM, Bianchi-Scarra G, Frebourg T, Joly P, Spatz A, Rubino C, Demenais E, Bressac-de Paillerets B; French Hereditary Melanoma Study Group. 2001. Sporadic multiple primary melanoma cases: CDKN2A germ line mutations with a founder effect. Genes Chromosomes Cancer 32:195-202.
2. Bertram CG, Gaut RM, Barrett JH, Pinney E, Whitaker L, Turner F, Bataille V, Dos Santos Silva I, J Swerdlow A, Bishop DT, Bishop JN. 2002. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 119:961-965.
3. Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Busam K, From E, Mujumdar U, Wilcox H, Begg CB; GEM Study Group. 2006, The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: An international population-based study. Cancer Epidemiol Biomarkers Prev 15:1520-1525.
4. Blackwood MA, Holmes R, Synnestvedt M, Young M, George C, Yang H, Elder D, Schuehter LM, Guerry D, Ganguly A. 2002. Multiple primary melanoma revisited. Cancer 94:2248-2255.
5. Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Zaluga E, Maleszka R, Kladny J, Gorski B, Cybulski C, Gronwald J, Kurzawski G, Eubinski J. 2005. CDKN2A common variants and their association with melanoma risk: A population-based study. Cancer Res 65:835-839.
6. Della Torre G, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, Peters G, Huot TJ, Bianchi-Scarra G, Lantieri F, Rodolfo M, Parmiani G, Pierotti MA. 2001. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: Functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 85:836-844.
7. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, Leachman SA. 2006. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 126:660-666.
8. Garbe C, Blum A. 2001. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 14:280-290.
9. Ghiorzo P, Gargiulo S, Pastorino L, Nasti S, Cusano R, Bruno W, Gliori S, Sertoli MR, Burroni A, Savarino V, Gensini E, Sestini R, Queirolo P, Goldstein AM, Scarra GB. 2006. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Hum Mol Genet 15:2682-2689.
10. Giles G, Staples M, McCredic M, Coates M. 1995. Multiple primary melanomas: An analysis of cancer registry data from Victoria and New South Wales. Melanoma Res 5:433-438.
11. Goldstein AM, Tucker MA. 2001. Genetic epidemiology of cutaneous melanoma. Arch Dermatol 137:1493-1496.
12. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril M-F, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, Mackie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Melanoma Genetics Consortium (GenoMEL). 2006. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66:9818-9828.
13. Harland M, Mistry S, Bishop DT, Bishop JA. 2001. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10:2679-2686.
14. Harland M, Taylor CF, Chambers PA, Kukalizch K, Randerson-Moor JA, Gruis NA, de Snoo FA, ter Huurne JAC, Goldstein AM, Tucker MA, Bishop DT, Bishop JN. 2005a. A mutation hotspot at the p14ARF splice site. Oncogene 24:4604-4608.
15. Harland M, Taylor CF, Bass S, Churchman M, Randerson-Moor JA, Holland EA, Mann GJ, Bishop T, Newton Bishop J. 2005b. Intronic sequence variants of the CDKN2A gene in melanoma pedigrees. Genes Chromosomes Cancer 43:128-136.
16. Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J. 2000. CDKN2A germ line mutations in individuals with multiple cutaneous melanomas. Cancer Res 60:6864-6867.
17. Hayward NK. 2003. Genetics of melanoma predisposition. Oncogene 22:3053-3062.
18. Helsing P, Faye R, Langmark F. 1997. Cutaneous malignant melanoma. Correlation between tumor characteristics and diagnostic delay in Norwegian patients. Eur J Dermatol 7:359-361.
19. Hewitt C, Wu CL, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N. 2002. Germline mutation of ARF in melanoma kindred. Hum Mol Genet 11:1273-1279.
20. Johnson TM, Hamilton T, Lowe L. 1998 Multiple primary melanomas. J Am Acad Dermatol 39:422-427.
21. Knappskog S, Geisler J, Arnesen T, Lillehaug JR, Lonning PE. 2006. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes Chromosomes Cancer 45:1155-1163.
22. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D. 1999. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128-132.
23. Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, Liu L, Knezetic J, Lassam NJ, Goggins M, Kern S. 2002. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: The familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94:84-96.
24. MacKie R, Andrew N, Lanyon WG, Connor JM. 1998. CDKN2A germline mutations in UK patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 111:269-272.
25. Mantelli M, Barile M, Ciotti P, Ghiorzo P, Lantieri F, Pastorino L, Catricala C, Torre GD, Folco U, Grammatico P, Padovani L, Pasini B, Rovini D, Queirolo P, Rainero ML, Santi PL, Sertoli RM, Goldstein AM, Bianchi-Scarra G; Societa Italiana Dermatologia; Gruppo Italiano Studi Epidemiologici in Dermatologia. 2002. High prevalence of the G101W germline mutation in the CDKN2A (p16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 107:214-221.
26. Mistry SH, Taylor C, Randerson-Moor JA, Harland M, Turner F, Barret JH, Whitaker L, Jenkins RB, Knowles MA, Bishop JA, Bishop DT. 2005. Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer 44:292-300.
27. Molven A, Grimstvedt MB, Steine S, Harland M, Avril MF, Hayward N, Akslen LA. 2005. A large Norwegian family with inherited malignant melanoma; multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 44:10-18.
28. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ. 1998. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338:879-887.
29. Pinsky PF, Kramer BS, Reding D, Buys S; PLCO Project Team. 2003. Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol 157:792-799.
30. Pjanova D, Engele L, Randerson-Moor JA, Harland M, Bishop DT, Newton Bishop JA, Taylor C, Debniak T, Lubinski J, Kleina R, Heisele O. 2007. CDKN2A and CDK4 variants in Latvian melanoma patients: Analysis of a clinic-based population. Melanoma Res 17:185-189.
31. Poetseh M, Lorenz G, Kleist B. 2002. Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. Cancer Genet Cytogenet 132:20-24.
32. Puig S, Malvehy J, Badenas C, Ruiz A, Jiménez D, Cuellar F, Azon A, Gonzalez U, Castel T, Campoy A, Herrero J, Marti R, Brunet-Vidal J, Mila M. 2005. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 23:3043-3051.
33. Quelle DE, Cheng M, Ashmun RA, Sherr CJ. 1997. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. Proc Natl Acad Sci 94:669-673.
34. Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ. 2006. Population-based study of the prevalence of family history of cancer: Implications for cancer screening and prevention. Genet Med 8:571-575.
35. ARF but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10:55-62.
36. Ruiz A, Puig S, Malvehy J, Lazaro C, Lynch M, Gimenez-Arnau AM, Puig L, Sanchez-Conejo J, Estivill X, Castel T. 1999. P16 mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 36:490-493.
37. Slingluff CL, Vollmer RT, Seigler HF. 1993. Multiple primary melanoma: Incidence and risk factors in 283 patients. Surgery 113:330-339.
38. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B. 1998. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 7:209-216.
39. Soufir N, Lacapere JJ, Bertrand G, Matichard E, Meziani R, Mirebeau D, Descamps V, Gerard B, Archimbaud A, Ollivaud L, Bouscarat F, Baccard M, Lanternier G, Saiag P, Lebbe C, Basset-Seguin N, Crickx B, Cave H, Grandchamp B. 2004. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma. Br J Cancer 90:503-509.
40. Soufir N, Ollivaud L, Bertrand G, Lacapere JJ, Deseamps V, Vitoux D, Lebbe C, Wolkenstein P, Dupin N, Saiag P, Basset-Seguin N, Grandchamp B. 2007. A French CDK4-positive melanoma family with a co-inherited EDNRB mutation. J Dermatol Sci 46:61-64.
41. Spica T, Portela M, Gerard B, Formicone F, Deseamps V, Crickx B, Ollivaud L, Archimbaud A, Dupin N, Wolkenstein P, Vitoux D, Lebbe C, Saiag P, Basset-Seguin N, Fargnoli MC, Grandchamp B, Peris K, Soufir N; MELAN-COHORT. 2006. The A148T variant of the CDKN2A gene is not associated with melanoma risk in the French and Italian populations. J Invest Dermatol 126:1657-1660.
42. Tucker MA, Boice JDm Jr, Hoffman DA. 1985. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr 68:161-189.
43. Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW. 1995. Mutations of the CDKN2A/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 4:1845-1852.
44. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC. 1996. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99.